

506,475

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
**WO 03/079919 A1**

- (51) International Patent Classification<sup>7</sup>: **A61B 19/08**
- (21) International Application Number: PCT/SE03/00419
- (22) International Filing Date: 13 March 2003 (13.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0200885-2 22 March 2002 (22.03.2002) SE
- (71) Applicant (for all designated States except US):  
**MÖLNLYCKE HEALTH CARE AB** [SE/SE]; P.O.Box 13080, S-402 52 Göteborg (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GELLERSTEDT, Fredrik** [SE/SE]; Bommen 4, S-439 94 Onsala (SE). **JOHANSSON, Helena** [SE/SE]; Ålandsgatan 3, S-411 32 Göteborg (SE).
- (74) Agent: **ALBIHNS STOCKHOLM AB**; P.O.Box 5581, Linnégatan 2, S-114 85 Stockholm (SE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: DRAPING PRODUCT WITH ADHESIVE EDGE



(57) Abstract: The present invention relate to a draping product (1-4) for surgical interventions, which on its underside is coated with adhesive along at least one edge thereof (5, 6, 7 and 8, respectively), said coating (12) extending fully or partly along the edge. According to the invention, the adherence force against skin of the adhesive is greater than 0.5 N/25 mm and the damage to Stratum Corneum of the part of the skin covered by the adhesive is, after removal of a draping product (1-4) attached to the skin, less than 30 % measured with SCT (Spectroscopic Colour Test).



WO 03/079919 A1

Draping product with adhesive edge

## TECHNICAL FIELD

- 5     The present invention relates to a draping product for surgical interventions, such as a surgical drape or a surgical towel, which on its underside is coated with adhesive along at least one of its edges, said coating extending fully or partly along the edge.

## 10    BACKGROUND OF THE INVENTION

- 15    Draping products, such as surgical drapes or surgical towels, with adhesive edge are often applied around a surgical site in order to ensure a barrier between the operative area and the part of the body of the patient that lies outside of the operative area. This barrier shall, on one hand, prevent bacteria and the like from the body of the patient to contaminate the operative area and, on the other hand, prevent blood, bacteria and the like from the operative area from contact with the body of the patient in the parts lying outside the operative area or from contaminating the operating table or the operating equipment. Thus, the edge of the draping product extending adjacent to the
- 20    operative area must adhere tightly against the skin and the strength of the adhesive bond must be great enough for the draping product to safely remain bonded for the loads it normally is subjected to during an operation.

- 25    At removal of the draping products used today, a part of Stratum Corneum, i.e. the upper layer of the skin, comes away with the draping product. This can lead to damage to the skin, especially for persons with sensitive skin, children under three years of age and persons more than seventy years of age, for example. The rests of skin attached to the adhesive edge of the removed

draping product prevents furthermore the draping product from being safely attached to the skin a second time. It often happens that the draping product has to be detached from its first application and re-applied to a new spot on the skin. Example of reason for such a detachment and re-application is a change of intervention technique during an ongoing operation or an adjustment of the location of the operative area before an operation. It is then a great risk that parts of the edge of a draping product of today become so poorly attached to the skin that the above mentioned barrier function is at risk.

The object of the present invention is to solve these problems and provide a draping product with adhesive edge, which safely adheres to skin and may be removed from a patient without risk for damage of the skin and which can be re-applied to skin without risk for the strength of the adhesive being reduced to much.

## SUMMARY OF THE INVENTION

According to the invention, this object is achieved by a draping product for surgical interventions, which on its underside is coated with adhesive along at least one edge thereof, said coating extending fully or partly along the edge, characterised in that the adherence force against skin of the adhesive is greater than 0.5 N/25mm, preferably greater than 1.0 N/25mm and more preferably greater than 1.2 N/25mm, and that the damage to Stratum Corneum of the part of the skin covered by the adhesive is, after removal of a draping product attached to the skin, less than 30%, preferably less than 20% and more preferably less than 10%, measured with SCT (Spectroscopic Colour Test).

In a preferred embodiment, the adhesive coating has a width perpendicular to the edge of the draping product less than 150 mm and is comprised of a

pressure sensitive adhesive (PSA), preferably a silicone elastomer, a hydrogel or a soft, tacky hot melt adhesive. The adhesive can be affixed to the underside of a strip of carrier material, the upper side of which being affixed to the underside of the draping product.

5

In an alternative embodiment, a separate strip is applied on the skin of a patient to provide a landing zone for at least a part of an edge of a draping product, the strip being characterised in that is coated on its underside with an adhesive having an adherence force against skin greater than 0.5 N/25mm, preferably greater than 1.0 N/25mm and more preferably greater than 1.2 N/25mm, and that the damage to Stratum Corneum of the part of the skin covered by the adhesive is, after removal of a draping product attached to the skin, less than 30%, preferably less than 20% and more preferably less than 10%, measured with SCT (Spectroscopic Colour Test). Furthermore, the strip has a width of 25-200 mm.

10  
15

The strip has preferably a smooth upper side providing an attachment surface for an adhesive edge of a draping product. Alternatively, the strip may be provided with affixing means on its upper side for attaching the strip to the underside of a draping product without adhesive edge.

20

The invention also relates to a draping product, which on its underside is coated with adhesive along at least one edge thereof, said coating extending fully or partly along the edge, characterised in that the adherence force against skin of the adhesive is greater than 0.5 N/25mm, preferably greater than 1.0 N/25mm and more preferably greater than 1.2 N/25mm, at a second application of the draping product against skin and that the adherence force against skin of the adhesive is reduced by less than 40%, preferably less than

25

30% and more preferably less than 20% at a second application of the draping product.

## BRIEF DESCRIPTION OF THE DRAWINGS SUMMARY OF THE INVENTION

The invention will now be described with reference to the enclosed figures, of which;

Fig. 1 schematically shows a planar view from above of a draping system for four draping products according to a preferred embodiment of the invention placed around an operation opening,

Fig. 2 shows a cross section along line II-II in figure 1,

Fig. 3 schematically shows measuring of adherence force against skin,

Fig. 4 schematically shows draping of draping products around an operation opening using a strip according to a second embodiment of the invention, and

Fig. 5 shows a cross section along line V-V in figure 4.

## DESCRIPTION OF EMBODIMENTS

In figure 1 is schematically shown a draping system comprising four draping products 1-4 applied around an operative area O on a patient not shown in the figure. Draping products 1 and 3 delimit two opposite, parallel edges 5,6 of the operative area and the draping products 2 and 4 delimit two opposite, parallel edges 7,8 being perpendicular to the edges 5,6. In order to prevent liquid from

the operative area from flowing under the edges 5-8 or bacteria from the area outside the operative area from penetrating into the operative area, the edges 5-8 are adhesively affixed to the skin of the patient. The draping products 1-4 may advantageously be surgical drapes and surgical towels denoted

5 Klinidrape® from Mölnlycke Health Care AB, Sweden, consisting of a laminate of three layers, a liquid absorbing top layer 9 of nonwoven, a liquid-tight middle layer 10 of polyethylene and a lower absorbent layer 11 of cellulose wadding or alternatively nonwoven. The top layer functions to absorb blood and other liquids emitted from the operative area and to prevent contamination of the patient from the operating staff and contamination of the operating staff and the operating theatre. The plastic film provides a barrier against liquid carried bacteria transport between the patient and the operative area and the layer of cellulose wadding enhances the comfort of the patient by absorbing sweat and preventing direct contact of the skin of the patient and the plastic film. The draping products 1-4 have also an adhesive coating 12 along their edges 5-8.

The main function of the adhesive coating 12 is to connect the draping product tightly to the skin of the patient so that liquid carried bacteria transport between the patient and the operative area is prevented and to securely fasten the draping product to the patient so that the product remains attached during all loads acting on the product during an operation. In this respect it is pointed out that the draping products extending in the longitudinal direction of the patient normally will hang down from the operating table and thereby are the most loaded products most of the time. Furthermore, the weight of the liquid that is absorbed or in other ways is taken up by the draping product, e.g. by pouches formed in or placed on the draping product, will load the fastening area of the draping product. The adhesive coating is dimensioned to safely manage the maximal load normally acting on the draping product.

The adhesive in the coating shall furthermore be skin friendly and allow removal of the draping product without damage to the skin around the operative area. This requirement is a great problem with the pressure sensitive adhesives now used as adhesive coatings for draping products. Such adhesives fasten often so hard to the skin so that parts of Stratum Corneum, i.e. the upper layer of the skin, stick to the adhesive and come loose from the skin when the fastening area of the draping product is loosened. This may lead to irritation and damage of the skin, especially for patients with a sensitive skin, such as persons over seventy years of age, children less than three years of age and patients having certain illnesses, such as psoriasis, or being subjected to certain treatments, such as treatment with cortisone. For such patients the draping products must sometimes be applied without use of the adhesive edge normally provided on the product, the draping products being attached in a different manner, e.g. by attaching the draping product with the aid of several pieces of fastening tape.

The adhesive attachment of the draping product is during use of the product almost solely subjected to shear forces. Consequently, the strength of the attachment can be increased by increasing the area of adhesive coating, i.e. by increasing the width of the adhesive coating along the edge of the draping product. It has, however, been shown that the width of the adhesive coating, i.e. its extension in a direction perpendicular to the edge, should not be larger than 200 mm. If the adhesive coating has a larger width, the application of the adhesive edge of the draping product is rendered difficult to a too large extent, which can cause formation of folds that can form channels for bacteria transport and thereby cause breaks in the barrier that should be provided by the adhesive edge.

Since the properties of skin varies from person to person, the adherence force against skin of the adhesive coating will vary for different patients. The values of adherence force stated below shall be measured by a method that is schematically illustrated in figure 3. Strips A of a carrier material coated with an adhesive, the adherence force of which is to be measured, and having a width of 25 mm are placed on the back of at least ten healthy persons of varying ages and sex and is maintained fastened to the skin during two minutes. Thereafter, the strips A are pulled with a rate of 25 mm/sec and the pulling force F1 is measured. The pulling angle, i.e. the obtuse angle formed between the skin surface and the pulled off portion of the strip A, shall be 135°. The adherence force against skin of the measured adhesive consists of the mean value of the force F1. Adhesives that can be used in a draping product according to the invention shall have an adherence force of at least 0.5 N/25mm.

Moreover, the damage to Stratum Corneum of the part of the skin covered by the adhesive shall after removal of a draping product attached to the skin be less than 30%, preferably less than 20% and more preferably less than 10%, measured with SCT (Spectroscopic Colour Test). The SCT-measuring shall be made in the way described in detail in P.J. Dykes, R. Heggie, S.A Hill, "effects of adhesive dressings on the stratum corneum of the skin", Journal of wound care, February, Vol 10, No. 2, 2001, which article is referred to for further details. The SCT-measuring shall be performed on at least ten person of varying sex and having healthy skin and be performed in the following way. Firstly, the skin in the centre of the test zone is coloured by application of a 12mm aluminium Finn chamber containing a 11 mm filter paper disc wetted with a 0.03ml 1% aqueous methylene blue. The Finn chamber shall be applied to the skin surface for 60 minutes. This is sufficient to produce an even colouring of the superficial layers of the Stratum Corneum. Then, the test



strips are applied to the coloured zones of the skin of the test persons and are applied thereon for 72 hours. After removal of the test strips after 72 hours, the stratum corneum shall be removed by "Skin surface biopsy procedure", which is described in R. Marks, R.P.R Dawber, "Skin surface biopsy; an improved technique for examination of the horny layer", Br J Dermatol 1971:84:117-123, to which is referred for further details. The biopsies shall thereafter be cut into smaller pieces and be placed in glass tubes containing 2ml dimethyl sulphoxide (DMSO). The glass tubes shall be shaken every 10-15 minutes over a period of two hours to ensure the dye extraction to be complete. The dimethyl sulphoxide extract shall then be centrifuged at 100g for 10 minutes to remove all fragments of stratum corneum. One millilitre of dimethyl sulphoxide shall then be transferred to a plastic cuvette to measure the optical density. The optical density shall be measured with a spectrophotometer. Initially, a blank cuvette containing dimethyl sulphoxide shall be scanned from 550-800 nm. Thereafter, an extracted skin surface biopsy from a coloured zone of the skin be scanned to determine the maximal absorbance. All subsequent measurements shall be performed at the wave length for maximal absorbance. The results are expressed as optical density units and are presented as a percentage of damage of Stratum Corneum relative to a reference sample of adjacent undamaged Stratum Corneum.

In table 1 below, the damage of Stratum Corneum caused by removal of adhesive from skin and measured by the above described spectroscopic colouring method (SCT) is shown for several different known products provided with adhesive; Allevyn from Smith & Nephew, Hull, Great Britain, Tielle hydropolymer dressing from Johnson & Johnson, Gargrave, Great Britain, Duoderm Extra Thin from ConvaTec Ltd, Deeside, Great Britain, Mepilex Border from Mölnlycke Health Care AB, Göteborg, Sweden and Biatain from Coloplast, Humlebaeck, Denmark.

Table 1

	Damage of Stratum corneum (%)
Allevyn adhesive	96.4
Tielle hydropolymer adhesive	90.9
Duoderm	81.8
Mepilex Border adhesive	-1.8
Biatain adhesive	87.3

5

From table 1 it is evident that only the adhesive on Mepilex Border fulfils the above mentioned requirements, said adhesive consisting of a silicone adhesive, elastomer Silgel 612 from Wacker Chemie GmbH, Germany. The negative value of skin damage is probably an effect of spreading of measuring data but can also relate to that the adhesive acts as a protection from the natural abrading of skin cells compared to the reference sample only being covered by gauze fabric during the measuring period.

10

15

It has been shown that strips with an adhesive having an adherence force of 0.5 N/25mm and giving a damage to Stratum Corneum of the part of the skin covered by the adhesive being less than 10% after removal of a draping product attached to the skin measured with SCT (Spectroscopic Colour Test) can be applied also to patients having sensitive skin and be removed without damage to or irritation of the skin.

20

Measurement of adherence force against skin with reapplication is made in the following way. Test strips are applied on the back of ten persons of varying

age and sex having a healthy skin. After two minutes the strips are pulled off in the same manner as described above with reference to figure 3 at a rate of 25mm/sec and the pull force  $F_1$  is measured. The pull angle shall be  $135^\circ$ . The strip is then reapplied on the skin on an untouched spot on the back and after two minutes the measurement of the pull force is repeated, wherewith the pull force  $F_2$  is obtained. The reduction of the pull force at the second pull relative to the first shall be less than 40%, preferably less than 30% and more preferably less than 20% and the pull force  $F_2$  at the second pull shall be larger than 0.5 N/25mm, preferably larger than 1.0 N/25mm and more preferably larger than 1.2 N/25mm.

Such a measurement was performed for adhesive coated strips from the commercially accessible products Klinidrape® Universal Set bBasic, art.No. 698740, from Mölnlycke Health Care AB, Göteborg, Sweden, Allegiance Convertors, REF 2915CE from McGaw Park, Illinois, USA and 3M Steri-Drape, 9000 from 3M, St. Paul, Minnesota, USA and for a strip of Klinidrape®-material, to which a strip of polyurethane was laminated and coated with the elastomer Silgel 612 from Wacker Chemie GmbH, Germany. The result of these measurements are shown in table 2 below.

Table 2

	Silicone adhesive	Klinidrape adhesive, U-set	Allegiance adhesive, U-set	3M adhesive U-set
$F_{\max}$ first (N/25mm)	1.71	0.72	0.80	0.82
$F_{\max}$ second (N/25mm)	1.44	0.35	0.37	0.41
Reduction of adherence force (%)	16	51	54	50

F <sub>mean value first</sub> (N/25mm)	1.14	0.50	0.52	0.60
F <sub>mean value second</sub> (N/25mm)	1.00	0.24	0.24	0.28
Reduction of adherence force (%)	12	51	53	53

These measurements makes it clear that Silgel 612 can function well as an adhesive for a draping product having an adhesive edge.

5      Silicone elastomers, for example a silicone elastomer for sale under the name  
 Silgel 612 manufactured by Wacker Chemie GmbH, Germany, are examples  
 of adhesives that can be used for draping products according to the present  
 invention. Some silicone elastomers have further the advantage of being  
 hydrophobic, which ensures that the edge of the draping product can be  
 10      sealingly attached to the skin. It is also conceivable to use hydrogels of a type  
 that tightly connects to the three-dimensional structure of the skin and in this  
 manner prevents passage of liquid through the adhesive coating and not or  
 only to small extent admit diffusion of liquid out of the hydrogel. However,  
 the use of hydrophobic adhesives is preferred.

15      It has been shown that a silicone elastomer with an adherence force of 1.5  
 N/25mm also fulfils the requirement that a damage to Stratum Corneum of the  
 part of the skin covered by the adhesive is less than 10% after removal of a  
 draping product attached to the skin measured with SCT (Spectroscopic  
 20      Colour Test). Such an elastomer is thus very suitable to use in draping  
 products.

A reason for soft adhesives to function well for affixing draping products to  
 skin is that the softness makes it possible for the adhesive to fill all

irregularities of the skin. This means that the adhesive covers a much larger part of the skin than the types of adhesives being used today for affixing draping products to the skin. Since a larger surface of the skin is used for attachment of a soft adhesive, the adherence to skin can be smaller than for a harder adhesive and still the soft adhesive can have a larger adherence force in N/25mm than the harder adhesive. This allows the soft adhesive to be pulled off the skin without other than loose parts of Stratum Corneum sticking to the adhesive.

10 In order to reduce the necessary width/length unit of the adhesive coating 12 and increase the safety margin in use of the draping products 1-4, the adherence force to skin of the adhesive coating 12 is advantageously larger than 1.0 N/25mm, preferably larger than 1.2 N/25mm.

15 With the hard adhesives used today for affixing draping products, the adhesive coating of the draping products is to a large extent covered by Stratum Corneum cells after removal from the skin. This leads to that their adhesive capacitance is reduced to such an extent that the edge of the draping product can not be reapplied to the skin. The application of such a draping product  
20 requires great caution since an incorrectly applied draping product can not in a simple manner be loosened and reapplied on a correct location but should be substituted by a fresh draping product.

25 In the embodiment disclosed in figures 1 and 2, the layer 12 of cellulose wadding is not extended along the edge of the draping product and the adhesive coating 12 is affixed to the plastic layer 10. In order to ensure that the adherence force of the adhesive against the underside of the draping product is larger than the adherence force against skin it is possible to affix the adhesive coating to a strip of material, e.g. a nonwoven or an appropriate plastic

material, to which the adhesive coating surely adheres with a larger force than against skin, and in turn affix the strip to the underside of draping product material with an adhesive that adheres well to the draping product material and to the strip. The strip can also consist of a laminate of a plastic film and a nonwoven, the nonwoven layer facing the adhesive coating, the plastic layer of the strip is affixed to the draping product material in an appropriate way, for example by glue.

A second embodiment of the invention is disclosed in figures 4 and 5, in which separate strips 13 coated with adhesive is used together with draping products 14-17 for accomplishing a similar draping of draping products around an operative area O as shown in figure 1. The strips 13 preferably consist of a plastic film 18, which on its upper side is coated with an adhesive 19 adhering well to the draping product material, e.g. an acrylate glue, and on its underside is coated with an adhesive 20 adhering well to skin. The adhesive 20 is an adhesive having the same properties as the adhesive 12 in the embodiment described above with reference to figures 1 and 2. Consequently, the draping products 14-17 lack adhesive coating. In a draping procedure with the aid of such a combination of draping product and strip, the strip is first applied along an edge of the operative area O, whereafter the edge of the draping product is applied to the strip and thereby is affixed to the adhesive 20 of the strip. By the fact that the draping product lacks adhesive coating that can stick to the product or wrong parts of the patient's body it is very easy to handle such a draping product and apply it to already affixed strip. In spite of this arrangement being a two-step procedure, the application of the draping product is facilitated in such an extent that the time for application will not be longer than for the application of draping products having an integrated adhesive edge. In figure 4, the draping of the draping products 14-17 is shown

in a final step, in which only the affixing of the edge of the draping product 16 to a strip 13 remains to be done.

5 The strip 13 should be made by a material, to which the adhesive facing the skin side, adheres with a greater force than to skin, and can in addition to a plastic layer consist of a nonwoven or a laminate of a nonwoven and a plastic layer. In order to allow a secure and easy application, the width of the strips 13 should preferably be 25-200 mm.

10 In an alternative embodiment of the strips 13, these lack adhesive coating on their upper side and co-operates with draping products 14-17 having adhesive edge of conventional type.

15 It is pointed out that all values of adherence force relate to adherence to dry skin. Moreover, all adhesive coatings of draping products or strips are provided with protective release layers, which are to be removed before application.

20 By the underside of the draping products or the strips is meant the side facing the body of a patient during use of the draping products or the trips.

25 The present invention can of course be used for other types of draping products than the products described in the embodiments, for example for surgical drapes having pre-prepared operative opening, around which an adhesive edge or adhesive edges extend. The scope of the present invention shall therefore include all known types of draping products intended to be affixed to the body of a patient.

The disclosed embodiments can of course be modified within the scope of the invention. The draping products can be manufactured of other materials than the described draping products, e.g. consist of one-layered draping products of textile or textile-like materials. The scope of invention shall therefore only be

5 restricted by the content of the enclosed patent claims.



### Claims

1. A draping product (1-4) for surgical interventions, which on its underside is coated with adhesive along at least one edge thereof (5, 6, 7, and 8, respectively), said coating (12) extending fully or partly along the edge, **characterised in** that the adherence force against skin of the adhesive is greater than 0.5 N/25mm, preferably greater than 1.0 N/25mm and more preferably greater than 1.2 N/25mm, and that the damage to Stratum Corneum of the part of the skin covered by the adhesive is, after removal of a draping product attached to the skin, less than 30%, preferably less than 20% and more preferably less than 10%, measured with SCT (Spectroscopic Colour Test).
2. A draping product according to claim 1, **characterised in** that the adhesive coating (12) has a width perpendicular to the edge of the draping product less than 150 mm.
3. A draping product according to claim 1 or 2, **characterised in** that the adhesive consists a silicone elastomer, a hydrogel or other soft, tacky adhesives.
4. A draping product according to claim 3, **characterised in** that the adhesive consists of a hydrophobic silicone elastomer.
5. A draping product according to any one of claims 1-4, **characterised in** that the adhesive is affixed to the underside of a strip of carrier material, the upper side of which being affixed to the underside of the draping product.

6. A strip (13) for affixing at least a part of an edge of a draping product (14-17) to the skin of a patient, **characterised in** that the strip (13) is coated on its underside with an adhesive (21) having an adherence force against skin greater than 0.5 N/25mm, preferably greater than 1.0 N/25mm and more preferably greater than 1.2 N/25mm, and that the damage to Stratum Corneum of the part of the skin covered by the adhesive is, after removal of a draping product attached to the skin, less than 30%, preferably less than 20% and more preferably less than 10%, measured with SCT (Spectroscopic Colour Test).
7. A strip according to claim 6, **characterised in** that it on its upper side is provided with fastening means (20) for attaching the strip (13) to the underside of a draping product (14-17).
8. A strip according to claim 6 or 7, **characterised in** that the strip has a width of 25-200 mm.
9. A draping product (1-4), which on its underside is coated with adhesive along at least one edge thereof (5,6,7 and 8, respectively), said coating extending fully or partly along the edge, **characterised in** that the adherence force against skin of the adhesive is greater than 0.5 N/25mm, preferably greater than 1.0 N/25mm and more preferably greater than 1.2 N/25mm, at a second application of the draping product against skin and that the adherence force against skin of the adhesive is reduced by less than 40%, preferably less than 30% and more preferably less than 20% at a second application of the draping product.




Fig. 2




Fig. 1




Fig. 3




Fig. 4




Fig. 5

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00419

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61B 19/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3669106 A (MARK S. SCHRADING ET AL), 13 June 1972 (13.06.72) --	1-9
A	US 5765566 A (ROBERT J. ROTHURM), 16 June 1998 (16.06.98), abstract, fig. --	1-9
A	US 5326616 A (DAVID BUTTERWORTH ET AL), 5 July 1994 (05.07.94), abstract, fig. --	1-9
A	EP 0051935 A2 (MINNESOTA MINING AND MANUFACTURING COMPANY), 19 May 1982 (19.05.82), abstract, fig. --	1-9

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

27 May 2003

Date of mailing of the international search report

06-06-2003

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Hélène Erikson/Els  
Telephone No. +46 8 782 25 00

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00419

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 5860420 A (GUENTHER WIEDNER ET AL),  19 January 1999 (19.01.99), abstract, fig.</p> <p style="text-align: center;">--  -----</p>	1-9

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00419

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	3669106	A	13/06/72	CA	969439 A	17/06/75
US	5765566	A	16/06/98	CA	2193218 A	25/01/96
				DE	769927 T	26/03/98
				DE	69504354 D,T	01/04/99
				EP	0769927 A,B	02/05/97
				SE	0769927 T3	
				US	5611356 A	18/03/97
				WO	9601594 A	25/01/96
US	5326616	A	05/07/94	AT	172627 T	15/11/98
				AU	656876 B	16/02/95
				AU	3844193 A	11/11/93
				BR	9301784 A	16/11/93
				CA	2095654 A	10/11/93
				DE	69321756 D,T	06/05/99
				DK	569255 T	05/07/99
				EP	0569255 A,B	10/11/93
				SE	0569255 T3	
				ES	2125304 T	01/03/99
EP	0051935	A2	19/05/82	SE	0051935 T3	
				AU	545844 B	01/08/85
				AU	7730381 A	20/05/82
				CA	1192825 A	03/09/85
				DE	3175625 D	00/00/00
				ES	273307 U,Y	16/05/84
				ES	528124 A	16/07/86
				ES	8608894 A	16/12/86
				JP	1420620 C	14/01/88
				JP	57115480 A	17/07/82
				JP	62028994 B	23/06/87
US	5860420	A	19/01/99	NONE		